Latest News

Latest News

Beyond Tolvaptan: The Next Generation of ADPKD Therapies

Beyond Tolvaptan: The Next Generation of ADPKD Therapies

Autosomal dominant polycystic kidney disease (ADPKD) is the most common inherited kidney disorder and the leading monogenic cause of kidney failure worldwide, affecting an estimated 12.5 million people globally. For nearly a decade, tolvaptan — a vasopressin V2...

read more
What Trauma Taught Me That Medical School Never Did

What Trauma Taught Me That Medical School Never Did

Medical school taught me how to diagnose disease, interpret imaging, manage pain, and treat injury. It taught me remarkably little about what chronic trauma does to the body. Like many physicians, I was trained to think of trauma primarily as a psychological injury,...

read more
CAR-T Therapy Explained: A Plain-English Guide

CAR-T Therapy Explained: A Plain-English Guide

CAR-T therapy is one of the most discussed cancer treatments of the past decade, and one of the most widely misunderstood. The name is an acronym. The science involves genetic engineering. The price runs to hundreds of thousands of pounds per patient. This guide...

read more

Join The Future Of Life Sciences Media

 

In a world overflowing with information, LifeScienceDaily.news stands apart as the dedicated space where life sciences professionals share what’s new, what’s next, and why it matters — all in real time.

 

 

Don’t wait for the media to pick up your story. Be the media.

More News

The False Economy of Returning to Manual PGD Processes

The False Economy of Returning to Manual PGD Processes

Across healthcare, financial pressure is forcing difficult decisions. Pharmacy teams are being asked to do more with less. Service expansion, dealing with NHS patients, workforce shortages remain acute, and every investment is being scrutinised. In this environment,...

read more
Compliant on Paper, Exposed in Practice

Compliant on Paper, Exposed in Practice

A pharmaceutical manufacturer completes a technology transfer. The validation protocols have been approved. Training records are complete, documentation has been reviewed, and every required signature has been collected. The project passes its milestones and moves...

read more
From Reactive Reviews to Predictive Regulatory Intelligence

From Reactive Reviews to Predictive Regulatory Intelligence

Every regulatory professional has experienced the same moment. After months, and sometimes years, of preparing a Chemistry, Manufacturing, and Controls (CMC) submission, the application is finally submitted to a health authority. At that point, the questions begin....

read more
The Patient as Healthcare’s Systems Integrator

The Patient as Healthcare’s Systems Integrator

Healthcare has undergone a remarkable digital transformation over the past two decades. Electronic health records, electronic prescribing, patient portals, telemedicine, artificial intelligence, and remote monitoring have fundamentally changed how healthcare is...

read more
The False Economy of Returning to Manual PGD Processes

The False Economy of Returning to Manual PGD Processes

Across healthcare, financial pressure is forcing difficult decisions. Pharmacy teams are being asked to do more with less. Service expansion, dealing with NHS patients, workforce shortages remain acute, and every investment is being scrutinised. In this environment,...

read more
Compliant on Paper, Exposed in Practice

Compliant on Paper, Exposed in Practice

A pharmaceutical manufacturer completes a technology transfer. The validation protocols have been approved. Training records are complete, documentation has been reviewed, and every required signature has been collected. The project passes its milestones and moves...

read more
From Reactive Reviews to Predictive Regulatory Intelligence

From Reactive Reviews to Predictive Regulatory Intelligence

Every regulatory professional has experienced the same moment. After months, and sometimes years, of preparing a Chemistry, Manufacturing, and Controls (CMC) submission, the application is finally submitted to a health authority. At that point, the questions begin....

read more
The Patient as Healthcare’s Systems Integrator

The Patient as Healthcare’s Systems Integrator

Healthcare has undergone a remarkable digital transformation over the past two decades. Electronic health records, electronic prescribing, patient portals, telemedicine, artificial intelligence, and remote monitoring have fundamentally changed how healthcare is...

read more

Featured Articles

FDA building exterior alongside pharmaceutical laboratory setting representing drug approval decisions

FDA Drug Approval Decisions

Last updated 31 July 2026. Covering target action dates from August to December 2026. The closing stretch of the third quarter has become the busiest regulatory window of 2026. Between early August and the end of September, the US Food and Drug Administration faces...
Pipette dispensing into lab vials with glowing DNA helix and genetic sequence data for Life Science Daily News

Life Science Daily News: Eight Months of Growth and a Global Community Taking Shape

Life Science Daily News launched in November 2025 with a simple premise: that researchers, biotech founders, healthcare professionals, communications specialists and industry professionals should be able to publish their own work directly to a specialist audience,...
gloved hands holding a glowing blue sample vial (labelled LOT: 24-B1, SAMPLE: GENO-) with a lab researcher working in the background.

CRISPR Gene Editing 2026: Rare Diseases, Cancer and Autoimmune

CRISPR gene editing in 2026 is no longer a technology to watch. It is a technology delivering results. Across three distinct disease areas, rare inherited conditions, haematologic and solid cancers, and autoimmune disease, clinical programmes are accumulating...
Three GLP-1 drug pipeline injection pens and oral tablets beside a clinical trial efficacy chart on a clipboard

The GLP-1 Drug Pipeline: Every Candidate to Watch in 2026

The GLP-1 drug pipeline has become one of the most consequential and closely watched in modern pharmaceutical history. In 2026, the class of glucagon-like peptide-1 receptor agonists is no longer defined solely by Ozempic and Wegovy. A new generation of oral tablets,...
Sjögren's disease diagnosis: close-up of a dry, irritated eye with eye drops being applied

Anti-Ro52 vs Anti-Ro60: Advancing Sjögren’s Disease Diagnosis

Autoantibody testing is a central part of autoimmune disease diagnosis, including Sjögren’s disease (SjD). The American College of Rheumatology and European Alliance of Associations of Rheumatology (ACR/EULAR) classification criteria for SjD incorporate ocular and...

Further News

Weekly News Roundup | 20 July 2026

Weekly News Roundup | 20 July 2026

Life science news 20 July 2026: the FDA approves the first oral PCSK9 inhibitor for high cholesterol, Eli Lilly makes the largest psychedelics deal in Big Pharma history, and a first-in-class breast cancer therapy wins regulatory clearance in a landmark week for...

read more
NAMs and Animal Testing: Separating Progress From Hype

NAMs and Animal Testing: Separating Progress From Hype

If you followed the headlines over the past two years, you could be forgiven for thinking animal testing in drug development is already on its way out. In December 2022, the FDA Modernization Act 2.0 removed the blanket legal requirement for animal studies to support...

read more
Clinical Trials Roundup | 17 July 2026

Clinical Trials Roundup | 17 July 2026

Celcuity's gedatolisib receives FDA approval as the first pan-PI3K and mTOR inhibitor for advanced breast cancer, Biogen's diranersen delivers detailed Phase 2 CELIA data showing tau reduction and cognitive benefit in early Alzheimer's disease, Novo Nordisk's...

read more
Biopharma H1 2026 Review: Deals, Drugs, and Pipeline Shifts

Biopharma H1 2026 Review: Deals, Drugs, and Pipeline Shifts

The first half of 2026 delivered one of the most consequential periods in recent biopharma history, reshaping competitive landscapes through record dealmaking, landmark regulatory approvals, and pivotal clinical breakthroughs. This biopharma H1 2026 review examines...

read more
CagriSema FDA Review: Novo Nordisk NDA Timeline Explained

CagriSema FDA Review: Novo Nordisk NDA Timeline Explained

The CagriSema FDA review has become one of the most closely watched regulatory processes in metabolic medicine. Novo Nordisk filed a New Drug Application for its once-weekly obesity combination in December 2025, and a decision is widely expected in the final quarter...

read more
The Evidence Gap in Precision Prevention

The Evidence Gap in Precision Prevention

Preventive medicine is entering a new era. Advances in genomics, biomarker testing, continuous monitoring technologies, imaging, and data analytics are enabling clinicians to identify disease risk with a level of precision that would have been unimaginable just a...

read more
Are Animal Models Limiting Progress in Product Development?

Are Animal Models Limiting Progress in Product Development?

While animal models have played a central role in safety assessment and biological research for decades, advances in cellular biology, computational modelling, and micro physiological systems are prompting scientists to explore new ways of generating human-relevant...

read more

Further News

Evaluating Retrieval Systems for Clinical AI

Clinical decision support is not new, and it does not have to be complex to work. If anything, the simpler it is, the more likely clinicians are to use it. The best-known earlier example is the WHO surgical safety checklist, developed by a team led by Atul Gawande,...

Women-Led Biotech Is Outperforming. Why Is Capital Lagging?

A new therapeutic can take a decade. Often hundreds of millions of dollars. Regulators checking the work at every stage along the way. So when a category of founders consistently delivers better returns on less capital, you'd expect investment patterns to reflect...

CSRD Reporting: What Has Changed for European Biotech

The European Union has rewritten its sustainability disclosure rules. The consequences for the life sciences sector are substantial. CSRD reporting was once expected to capture tens of thousands of companies across the bloc. It now applies to a far smaller group of...

Microalgae Biomaterials: Where the Carbon Math Holds, and Where it Fails

A research team at the University of Colorado Boulder took a marine dinoflagellate called Pyrocystis lunula, mixed it into 4 wt% sodium alginate, crosslinked the gel ionically in calcium chloride, and extruded it through a Cellink BIO X bioprinter into printed grids...

NHS Golden Jubilee First Scottish Hospital to Adopt Steriwave

NHS Golden Jubilee Becomes First Scottish Hospital to Adopt Light-Activated Infection Prevention Technology to Prevent Surgical Site Infections GLASGOW — Scotland’s flagship orthopaedic hospital, NHS Golden Jubilee, has become the first in the country to adopt an...

Receptor.AI and Sethera Partner on AI-Guided Peptide Drug Discovery

Receptor.AI and Sethera Therapeutics Form Integrated Discovery Alliance for AI-Guided Polymacrocyclic Peptide Medicines Collaboration combines Sethera's proprietary enzymatic polymacrocyclisation and trillion-scale encoded screening with Receptor.AI's physics-based...

Dual and Triple Agonists Explained: GLP-1, GIP and Glucagon

Obesity and diabetes medicine has moved a long way from the single-hormone era. Dual and triple agonists are engineered molecules that switch on two or three hormone receptors at once. They now dominate the late-stage pipeline, and the highest doses tested have...

Ziltivekimab ZEUS Trial: What the Null Result Means

The ziltivekimab ZEUS trial has produced one of the more instructive negative results in recent cardiovascular medicine. Novo Nordisk announced headline results on 31 July 2026 showing that its once-monthly interleukin-6 inhibitor ziltivekimab lowered inflammation...

How the Gut-Brain-Metabolism Axis Is Reshaping Targeted Therapy

For decades, the fields of oncology, neuroscience, and microbiology operated in distinct silos within therapeutic research and clinical practice. Modern drug discovery, however, is rapidly witnessing a paradigm shift toward systemic biology. Researchers increasingly...

Singapore Radiopharmaceutical Market: How H2 2026 Looks

The Singapore radiopharmaceutical market enters the second half of 2026 with more clinical capacity, more research output and a heavier regulatory calendar than at any previous point. New imaging infrastructure came online at the end of 2025, first-in-human data from...

Why True Health Foods Need Evidence, Not Fashion

Functional foods have entered the mainstream, but adding a recognised ingredient is not the same as creating a credible product. A cardiologist argues that the category’s next phase will be won on scientific rationale, dose and honest communication, not on the length...

How Clinical Research Is Transforming the Future of Sarcoma Care

Rare cancers present one of the greatest challenges in modern oncology. Individually uncommon but collectively accounting for around one in five cancer diagnoses worldwide, they have historically attracted less research funding, fewer clinical trials and limited...

Want to Be Part of the Next Chapter in Life Sciences Media?

 

LifeScienceDaily.news is building a new kind of platform where innovators, researchers, and industry leaders tell their own stories and shape the narrative of what’s next in life sciences. Share your story and lead the conversation.

 

 

Don’t wait for the media to pick up your story. Be the media.

See More Articles

Want to Be Part of the Next Chapter in Life Sciences Media?

 

LifeScienceDaily.news is building a new kind of platform where innovators, researchers, and industry leaders tell their own stories and shape the narrative of what’s next in life sciences. Share your story and lead the conversation.

 

 

Don’t wait for the media to pick up your story. Be the media.